Scandion is a biotechnology company. The company develops pharmaceuticals for the treatment of cancer containing drug-resistant cell clones. The leading product of the company, SCO-101, has shown to improve the effect of certain standard cancer treatments during preclinical studies. The head office of the company is located in Copenhagen.

Quotes for Scandion Oncology

Right Now

+/-
%
Latest
High
Low
Volume
Turnover ()
Time (Latest trade)

Board

CEO

  • Bo Rode Hansen

Chairperson of the Board

  • Peter Høngaard

Board

  • Annie Rasmussen
  • Bo Hansen
  • Carl Borrebäck
  • Christian Vinding Thomsen
  • Jørgen Bardenfleth
  • Thomas Feldthus

Videos

Largest Owners

Name Capital % Votes % Date
Dan Peters 18,40 18,40 2025-04-28
Avanza Pension 4,47 4,47 2025-04-28
Mukhlis Shamon 3,15 3,15 2025-04-28
Sparekassen Kronjylland - General Client Account 1,96 1,96 2025-04-28
Che Harald Mårten Vågerö 1,58 1,58 2025-04-28
Johan Haag 1,30 1,30 2025-04-28
Rossen Denmark Aps 1,19 1,19 2025-04-28
Marianne Stenlund 1,06 1,06 2025-04-28
Nordnet Pensionsförsäkring 1,06 1,06 2025-04-28
Thomas Nordin 0,88 0,88 2025-04-28